期刊文献+

HPLC-荧光法测定替米沙坦血药浓度的方法学考察 被引量:1

Determination of telmisartan in human plasma by HPLC-fluorescence
下载PDF
导出
摘要 目的:采用HPLC-荧光法测定替米沙坦的血浆药物浓度。方法:采用Agillent Zorbax SB-C18色谱柱(150mm×4.6mm,5μm),流动相为水-乙腈(58∶42,H3PO4调pH为4~5),流速1.0ml/min,荧光激发波长300nm,发射波长380nm。结果:替米沙坦浓度在5~200ng/ml范围内与峰面积具有良好的线性关系,最低检测限为5ng/ml。结论:该法准确可靠,适用于替米沙坦的血药浓度测定。 Objective:To determine the concentration of telmisartan in human plasma by HPLC-fluorescence method. Methods:Separation was achieved on Agillent Zorbax SB-CI8 column ( 150 mmx4.6 mm,5 μm).The mobile phase consisted of water-acetonitrile(58:42, pH4-5),with a flow rate of 1.0 ml/min,and detection with a fluorescence detector set at an exci-tation wavelength of 300 nm and emission wavelength of 380 nm. Results:A linearity of telmisartan concentration curve was obtained in a range of 5-200 ng/ml.The detection limit was 5 ng/ml.Conclusion:This method is accepted to determine the concentration of telmisartan.
出处 《中国医药导报》 CAS 2008年第8期28-29,共2页 China Medical Herald
关键词 替米沙坦 血药浓度 HPLC Telmisartan Blood-plasma concentration HPLC
  • 相关文献

参考文献2

二级参考文献30

  • 1[10]NAKASHIMA M, UMEMURA K. The clinical pharmacology of losartan in Japanese subjects and patients[J]. Blood Press Suppl,1996,2:62-66.
  • 2[11]SONG JC, WHITE CM. Pharmacologic, pharmacokinetic, and therapeutics differences among angiotensin Ⅱreceptor antagonists [J]. Pharmacotherapy, 2000,20(2):130-139.
  • 3[12]NEUTEL JM, KLEIN C, MEINICKE TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications[J].Blood Press,2002,11(5):302-309.
  • 4[13]PRASAD PP, YEH CM, GURRIERI P, et al. Pharmacokinetics of multiple doses of valsartan in patients with heart failure[J]. J Cardiovasc Pharmacol,2002,40(5):801-807.
  • 5[14]SMITH DH, MATZEK KM, KEMPTHORNE-RAWSOWL J. Dose response and safety of telmisartan in patients with mild to moderate hypertension[J]. J Clin Pharmacol,2000,40(12 Pt 1):1380-1390.
  • 6[15]SASAKI M, FUJIMURA A, HARADA K, et al. Clinical pharmacology of multiple-dose losartan an angiotensin Ⅱ receptor antagonist, in patients with essential hypertension[J]. J Clin Pharmacol, 1996, 36(5):403-408.
  • 7[16]RUILOPE L. Human pharmacokinetic/pharmacodynemic profile of irbesartan: a new potent angiotensin Ⅱ receptor antagonist[J]. J Hypertens Suppl,1997 ,15 (7):S15-S20.
  • 8[17]McCLELLAN KJ, GOA KL. Candesartan cilexetil. A review of its use in essential hypertension[J]. Drugs,1998,56(5):847-869.
  • 9[18]PHILIPP T, LETZEL H, ARENS HJ. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension[J]. J Hum Hypertens,1997 ,11 Suppl 2:S67-S68.
  • 10[19]McGILL JB, REILLY PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized ,double-blind, placebo-controlled, parallel-group trial [J]. Clin Ther,2001, 23(6):833-850.

共引文献44

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部